Systemic Pharmacological Treatments for Chronic Plaque Psoriasis

Psoriasis

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation

JAMA Dermatol

Armstrong AW, Gondo GC, Merola JF, Roberts AM, Pérez-Chada LM, Balak DMW, Eakin GS, Read C, Le ST, Gutierrez Y, Bhutani T, Blauvelt A, Duffin KC, Fakharzadeh S, Feldman SR, Gelfand JM, Gladman DD, Glick B, Green LJ, Han G, Hawkes JE, Hwang ST, Johnsen N, Kalb RE, Kircik L, Langley RG, Lebwohl MG, Lewitt GM, Maverakis E, Prussick R, Reddy SM, Rosen CF, Scher JU, Siegel EL, Wallace EB, Weinberg JM, Yamauchi PS, Yosipovitch G, Liao W, Remission Workgroup of the National Psoriasis Foundation

doi: 10.1001/jamadermatol.2025.1625

Psoriasis

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

J Eur Acad Dermatol Venereol

Miao Y, Beauchet A, Piram M, McPherson T, Torres T, Yesli Y, Aubert H, Bodemer C, Bertoli C, Tardieu M, Hubiche T, Bonniaud B, Neri I, Chessa MA, Lasek A, Prignano F, Barbarot S, Bursztejn AC, Leducq S, Sergeant M, Puzenat E, Chiaverini C, Sigg N, Mallet S, Miquel J, Pourchot D, Patel KX, Burden-Teh E, Flohr C, Di Lernia V, Mahé E, GrPso of the Société Française de Dermatologie; Groupe de Recherche de la Société Française de Dermatologie Pédiatrique

doi: 10.1111/jdv.70108

Allergic Diseases

Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis

J Allergy Clin Immunol

Chu AWL, Oykhman P, Chu X, Rayner DG, Bhangal S, Dam A, Xu J, Sheikh J, Trayes KP, Frazier WT, Lang DM, Beck LA, Mathur SK, Waserman S, Thabane L, Asiniwasis RN, Runyon L, Moellman J, Oliver ET, Chan J, Cole EF, Baker DR, Khan DA, Ben-Shoshan M, Wheeler KE, Eftekhari S, Gardner DD, Winders T, Flindall M, Tattrie J, Bernstein JA, Saini SS, Chu DK

doi: 10.1016/j.jaci.2025.06.004

Psoriasis

Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Br J Dermatol

Phan DB, Laws P, Smith CH, Griffiths CEM, Kirby B, Hughes O, Rogers G, Alabas OA, Lunt M, Warren RB, Yiu ZZN

doi: 10.1093/bjd/ljag098

Psoriasis

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

Adv Ther

Deodhar S, Loganathan S, Kadadanamari Subbarama Reddy R, Ranganna GM, Liu S, Hummel MA, Daniluk S, Hanczewska A, Vekovska K, Zegadlo-Mylik M, Pulka G, -Holz EW

doi: 10.1007/s12325-025-03240-5

Psoriasis

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

J Am Acad Dermatol

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE, Ramessur R, Gelfand JM, Merola JF, Winthrop KL, Torres T

doi: 10.1016/j.jaad.2025.11.033

Psoriasis

Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)

J Am Acad Dermatol

Strober B, Kwiatkowski H, Lavasani L, Semeco J, Lakshminarasimhan B, Lebwohl M, Gottlieb AB

doi: 10.1016/j.jaad.2025.08.089

Psoriasis

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

J Eur Acad Dermatol Venereol

Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, Bansal A, Dahale SS, Martin R, Paguet B, Magnolo N, Kingo K

doi: 10.1111/jdv.70155

Further Publications Dermatology

Real-world Evidence of Self-reported Treatments, Signs, and Symptom Burden in Chronic Hand Eczema: Findings from the Multinational CHECK Study

Acta Derm Venereol

Molin S, Fargnoli MC, Crepy MN, Giménez-Arnau AM, Brignoli L, Le Calvé P, Krupka M, Norlin JM, Apfelbacher C, Bewley A

doi: 10.2340/actadv.v106.44493

Related content

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation

Drug survival of systemic treatments for severe paediatric psoriasis: An international retrospective study

Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis

Using biologic therapies as first-line systemic treatment for psoriasis: A cohort study following the target trial emulation framework from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)

Multiple Switches Between Adalimumab-fkjp and Reference Adalimumab in Moderate-to-Severe Chronic Plaque Psoriasis: A Multicenter, Double-Blind, Parallel Group, Randomized Clinical Trial for Interchangeability

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

Real-world treatment patterns in patients with generalized pustular psoriasis (GPP)

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

Real-world Evidence of Self-reported Treatments, Signs, and Symptom Burden in Chronic Hand Eczema: Findings from the Multinational CHECK Study